Awanui Group’s quest to improve lab diagnostics in New Zealand: Q&A with Anoop Singh (Part 1)

A.SinghA.Singh
W.WongW.Wong
BulletArticle
Leaders In Conversation C-Suite Perspectives
分享此連結：
複製連結
How Awanui Group drives diagnostic excellence in New Zealand: Q&A with Anoop Singh (Part 1)

As CEO of Awanui Group, Anoop Singh looks after one of the most important institutions in New Zealand’s laboratory medicine ecosystem. In this Q&A with Wing Lam Wong, General Manager of Roche Diagnostics New Zealand, Singh introduces his organisation and discusses how partnerships with IVD suppliers, community groups, governmental entities and other key stakeholders are integral to the services that Awanui Group provides across the care continuum in New Zealand.

This is part 1 of 2 in a Q&A series with Mr Singh. You can click here for part 2. 

分享此連結：
複製連結

更多相同主題

Accelerating environmental sustainability in clinical labs: Q&A with Prof Tony Badrick

Awanui Group’s business transformation journey: Q&A with Anoop Singh (Part 2)

建議的主題

SequencingRED 2020Rare Diseases
接下來讀取
  • C-Suite Perspectives, Event Coverage, Healthcare Transformation, Management, RED 2024
Dr William Morice II’s visions and considerations for building a global diagnostics ecosystem
How Awanui Group drives diagnostic excellence in New Zealand: Q&A with Anoop Singh (Part 1)
  • C-Suite Perspectives, Leaders In Conversation, Management
Awanui Group’s quest to improve lab diagnostics in New Zealand: Q&A with Anoop Singh (Part 1)
‘Real world evidence’ and clinical labs: a brief introduction
  • Healthcare Transformation, Management, Operations, Population Health Management
‘Real world evidence’ and clinical labs: a brief introduction
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
  • Disease Area, Healthcare Transformation, Histopathology, Leaders In Conversation, Management, Oncology, Operations
‘Chasing the Invisible’ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
Scroll to Top